Experimental Hematology
Volume 38, Issue 8 , Pages 696-706 , August 2010

FET family proto-oncogene Fus contributes to self-renewal of hematopoietic stem cells

  • Takeaki Sugawara

      Affiliations

    • Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
    • Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
    • Division of Hematology, Chiba University Hospital, Chiba, Japan
    • Division of Transfusion and Cell Processing, Chiba University Hospital, Chiba, Japan
    • ,
  • Hideyuki Oguro

      Affiliations

    • Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
    • ,
  • Masamitsu Negishi

      Affiliations

    • Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
    • ,
  • Yohei Morita

      Affiliations

    • Division of Stem Cell Therapy, Center for Stem Cell Biology and Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    • ,
  • Hitoshi Ichikawa

      Affiliations

    • Genetics Division, National Cancer Center Research Institute, Tokyo, Japan
    • ,
  • Toru Iseki

      Affiliations

    • Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
    • Division of Hematology, Chiba University Hospital, Chiba, Japan
    • Division of Transfusion and Cell Processing, Chiba University Hospital, Chiba, Japan
    • ,
  • Osamu Yokosuka

      Affiliations

    • Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
    • ,
  • Hiromitsu Nakauchi

      Affiliations

    • Division of Stem Cell Therapy, Center for Stem Cell Biology and Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    • Nakauchi Stem Cell and Organ Regeneration Project, JST, ERATO, Tokyo, Japan
    • ,
  • Atsushi Iwama

      Affiliations

    • Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
    • CREST, Sanbancho, Chiyoda-ku, Tokyo, Japan
    • Corresponding Author InformationOffprint requests to: Atsushi Iwama, M.D., Ph.D. Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

Received 21 January 2010 ,Revised 7 April 2010 ,Accepted 13 April 2010.

References 

  1. Crozat A, Aman P, Mandahl N, et al. Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993;363:640–644
  2. Rabbitts TH, Forster A, Larson R, et al. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t (12;16) in malignant liposarcoma. Nat Genet. 1993;4:175–180
  3. Shimizu K, Ichikawa H, Tojo A, et al. An ETS-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc Natl Acad Sci U S A. 1993;90:10280–10284
  4. Ichikawa H, Shimizu K, Hayashi Y, et al. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 1994;54:2865–2868
  5. Kong XT, Ida K, Ichikawa H, et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood. 1997;90:1192–1199
  6. Pérez-Losada J, Pintado B, Gutiérrez-Adán A, et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene. 2000;19:2413–2422
  7. Riggi N, Cironi L, Provero P, et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res. 2006;66:7016–7023
  8. Ichikawa H, Shimizu K, Katsu R, et al. Dual transforming activities of the FUS (TLS)-ERG leukemia fusion protein conferred by two N-terminal domains of FUS (TLS). Mol Cell Biol. 1999;19:7639–7650
  9. Pereira DS, Dorrell C, Ito CY, et al. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. Proc Natl Acad Sci U S A. 1998;95:8239–8244
  10. Warner JK, Wang JC, Takenaka K, et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia. 2005;19:1794–1805
  11. Bertolotti A, Lutz Y, Heard DJ, et al. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 1996;15:5022–5031
  12. Prasad DDK, Ouchida M, Lee L, et al. TLS/FUS fusion domain of TLS/FUS-ERG chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene. 1994;9:3717–3729
  13. Zinszner H, Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev. 1994;8:2513–2526
  14. May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 1993;13:7393–7398
  15. Bertolotti A, Bell B, Tora L. The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties. Oncogene. 1999;18:8000–8010
  16. Lerga A, Hallier M, Delva L, et al. Identification of an RNA binding specificity for the potential splicing factor TLS. J Biol Chem. 2001;276:6807–6816
  17. Yang L, Embree LJ, Tsai S, et al. Oncoprotein TLS interacts with serine-arginine proteins involved in RNA splicing. J Biol Chem. 1998;273:27761–27764
  18. Yang L, Embree LJ, Hickstein DD. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol Cell Biol. 2000;20:3345–3354
  19. Yang L, Chansky HA, Hickstein DD. EWS/Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem. 2000;275:37612–37618
  20. Chansky HA, Hu M, Hickstein DD, et al. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res. 2001;61:3586–3590
  21. Hicks GG, Singh N, Nashabi A, et al. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet. 2000;24:175–179
  22. Kuroda M, Sok J, Webb L, et al. Male sterility and enhanced radiation sensitivity in TLS–/– mice. EMBO J. 2000;19:453–462
  23. Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321–330
  24. McMahon KA, Hiew SY, Hadjur S, et al. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell. 2007;1:338–345
  25. Jude CD, Climer L, Xu D, et al. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell. 2007;1:324–337
  26. Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 2008;3:207–220
  27. Loughran SJ, Kruse EA, Hacking DF, et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol. 2008;9:810–819
  28. Aman P, Panagopoulos I, Lassen C, et al. Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics. 1996;37:1–8
  29. Kim I, He S, Yilmaz HÖ, Kiel MJ, et al. Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptors. Blood. 2006;108:737–744
  30. NijNik A, Woodbine L, Marchetti C, et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature. 2007;447:686–691
  31. Rossi DJ, Bryder D, Seita J, et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cell with age. Nature. 2007;447:725–730
  32. Rogakou EP, Pilch DR, Orr AH, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858–5868
  33. Allsopp RC, Morin GB, DePinho R, et al. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood. 2003;102:517–520
  34. Choudhury AR, Ju Z, Djojosubroto MW, et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet. 2007;39:99–105
  35. Miyamoto K, Araki KY, Naka K, et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell. 2007;1:101–112
  36. Takahashi A, Higashio F, Aoyagi M, et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res. 2003;63:8338–8344
  37. Bertrand P, Akhmedov AT, Delacote F, et al. Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation. Oncogene. 1999;18:4515–4521
  38. Baechtold H, Kuroda M, Sok J, et al. Human 75-kDa DNA-pairing protein is identical to the pro-oncoprotein TLS/FUS and is able to promote D-loop formation. J Biol Chem. 1999;274:34337–34342
  39. Gardiner M, Toth R, Vandermoere F, et al. Identification and characterization of FUS/TLS as a new target of ATM. Biochem J. 2008;415:297–307
  40. Zhou BBS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433–439
  41. Wang X, Arai S, Song X, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 2008;454:126–130
  42. Fujii R, Takumi T. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci. 2005;118:5755–5765
  43. Kwiaatkowski TJ, Bosco DA, LeClerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–1208
  44. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in the FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1205–1211
  45. Li H, Watford W, Li C, et al. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J Clin Invest. 2007;117:1314–1323
  46. Mills KI, Walsh V, Gilkes AF, et al. High TLS/FUS expression in acute myeloid leukemia samples. Br J Haematol. 2000;108:316–321
  47. Perrotti D, Bonatti S, Trotta R, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J. 1998;17:4442–4455
  48. Perroti D, Iervolino A, Cesi V, et al. BCR-ABL prevents c-Jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CβII-dependent pathway. Mol Cell Biol. 2000;20:6159–6169

PII: S0301-472X(10)00149-9

doi: 10.1016/j.exphem.2010.04.006

Experimental Hematology
Volume 38, Issue 8 , Pages 696-706 , August 2010

Article Tools

* Image Usage & Resolution